Trump Nominates Chris Klomp as Deputy Secretary of Health and Human Services

2026-06-26

The BareStory

President Donald Trump announced on Thursday the nomination of Chris Klomp to serve as the deputy secretary of the Department of Health and Human Services (HHS). If confirmed by the Senate, the 45-year-old Klomp will serve as the second-in-command to HHS Secretary Robert F. Kennedy Jr. Klomp currently holds multiple roles within the department, including chief counselor and director of the Center for Medicare.

Trump praised Klomp's leadership and business background, stating that Klomp has done an excellent job managing day-to-day operations and Medicare. Trump also claimed that Klomp secured voluntary, undisclosed drug price reductions with 17 pharmaceutical companies and drove reforms that lowered U.S. drug prices. Department officials stated that Klomp brings decades of management experience to the role, noting that HHS is currently working to modernize its auditing and use artificial intelligence to detect fraudulent patterns.

As chief counselor, Klomp has executed several high-profile leadership changes, including facilitating key appointments at health agencies. Administration officials stated that Klomp carried out the May dismissal of former Food and Drug Administration Commissioner Marty Makary, and he has frequently represented HHS at major health conferences. However, his actions have also drawn criticism; a former senior official claimed that Klomp has undermined Kennedy by independently making personnel decisions and attempting to terminate employees without Kennedy's knowledge. Additionally, a Democratic Senate aide claimed Klomp was appointed to monitor Kennedy's actions.

Before joining HHS, Klomp assisted with the 2020 federal COVID-19 response, served as the chief executive officer of Collective Medical, and held board positions at Nomi Health and Maven Clinic. The Senate Finance Committee will decide whether to advance his nomination, though his confirmation prospects remain uncertain due to political disagreements within the committee regarding Trump's policies and Kennedy's leadership.

Left Perspective

Exposing Secretive Corporate Pacts
Monitoring Unorthodox Executive Overreach
Challenging Corporate Regulatory Capture

Right Perspective

Ensuring Seamless Operational Continuity
Harnessing Private Sector Efficiency
Upholding Strict Institutional Order

Left Perspective

• Exposing Secretive Corporate Pacts Reformers prioritize absolute transparency and public accountability when regulating the essential healthcare sector. Relying on voluntary, undisclosed price agreements with 17 pharmaceutical companies, as praised by the administration, creates a dangerous precedent of backroom diplomacy rather than enforceable, systemic cost controls. Without public oversight and statutory mandates, these voluntary concessions fail to offer long-term protections for vulnerable patients against predatory corporate pricing.

• Monitoring Unorthodox Executive Overreach Protecting the integrity of federal health agencies requires robust internal checks to safeguard scientific standards against ideological erosion. If the claims of Senate aides are accurate, appointing Klomp to monitor the actions of Secretary Robert F. Kennedy Jr. serves as a vital defensive measure to prevent erratic leadership from destabilizing agencies like the FDA. Ensuring that experienced administrative hands guide personnel actions and policy transitions prevents the dangerous politicization of public health.

• Challenging Corporate Regulatory Capture A progressive approach to public health demands strict boundaries between private healthcare profits and regulatory enforcement. Klomp's extensive background as the former CEO of Collective Medical and board member for private health firms like Nomi Health and Maven Clinic raises immediate concerns about conflicted loyalties. Placing private-sector executives at the helm of HHS risks steering public policy toward market-friendly solutions rather than prioritizing equitable, universal access to care.

Right Perspective

• Ensuring Seamless Operational Continuity Traditionalists value stability, orderly governance, and the preservation of established institutional systems. Promoting an experienced insider who currently directs the Center for Medicare guarantees that the massive, complex machinery of the federal health apparatus remains functional during a leadership transition. This administrative continuity is essential for protecting the millions of citizens who rely on the daily, uninterrupted operation of state welfare systems.

• Harnessing Private Sector Efficiency Enhancing the fiscal responsibility of the state requires importing pragmatic business principles and technological innovation into bloated government bureaucracies. Utilizing artificial intelligence to detect fraudulent patterns and modernizing HHS auditing systems directly aligns with the goal of protecting taxpayer resources and upholding the rule of law. Furthermore, leveraging private-sector negotiating tactics to secure voluntary drug price reductions proves that collaborative approaches can achieve public welfare goals without heavy-handed government mandates.

• Upholding Strict Institutional Order Maintaining an orderly executive branch requires absolute adherence to the chain of command and clear bureaucratic structures. Allegations that Klomp undermined the designated Secretary by independently making personnel decisions and attempting unauthorized terminations present a severe threat to administrative stability. Traditionalists view such internal insubordination as a disruption to governance that fosters institutional paralysis and weakens the unified authority of the executive branch.

How it may affect me

As a U.S. reader:

• You may experience uninterrupted Medicare services during the leadership transition because an experienced insider who already manages day-to-day Medicare operations is nominated for the role.

• Your prescription medication costs could be affected by the administration's reliance on voluntary, undisclosed price agreements with pharmaceutical companies, which supporters say lower drug prices but critics argue fail to provide reliable, long-term cost protections.

• Your taxpayer dollars could be utilized more efficiently as the department implements artificial intelligence and updated auditing systems to detect fraudulent spending patterns.

• The future direction of federal healthcare policies and regulations could tilt toward market-friendly solutions due to the nominee's extensive background as an executive in the private healthcare sector.

• Ongoing leadership conflicts or uncertainty surrounding the Senate confirmation process could lead to administrative delays or instability within key public health agencies like the Food and Drug Administration.

Trump Nominates Chris Klomp as Deputy Secretary of Health and Human Services

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at